Evaluation of the OARSI and OMERACT-OARSI set of responder criteria in patients treated with Hylan G-F 20 for knee osteoarthritis.

被引：0
|
作者：
Bell, MJ
Bellamy, N
Goldsmith, CH
Tugwell, P
Torrance, GW
Raynauld, JP
Polisson, R
Pericak, D
Walker, V
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Univ Queensland, St Lucia, Qld 4067, Australia
[3] McMaster Univ, Hamilton, ON, Canada
[4] Univ Ottawa, Ottawa, ON, Canada
[5] Univ Montreal, Montreal, PQ, Canada
[6] Genzyme Corp, Cambridge, MA USA
[7] Innovus Res Inc, Burlington, ON, Canada
来源：
ARTHRITIS AND RHEUMATISM | 2003年 / 48卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1214
引用
收藏
页码：S482 / S482
页数：1
相关论文
共 50 条
  • [31] Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis
    Raynauld, JP
    Goldsmith, CH
    Bellamy, N
    Torrance, GW
    Polisson, R
    Belovich, D
    Pericak, D
    Tugwell, P
    OSTEOARTHRITIS AND CARTILAGE, 2005, 13 (02) : 111 - 119
  • [32] Examining minimal perceptible clinical improvement criteria in patients treated with hylan G-F 20 for knee ostecarthritis
    Bellamy, N
    Bell, MJ
    Goldsmith, CH
    Torrance, GW
    Raynauld, J
    Tugwell, P
    Polisson, R
    Pericak, D
    Walker, V
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 357 - 357
  • [33] Hylan G-F 20 for knee Osteoarthritis (OA): A Cochrane review.
    Bellamy, N
    Campbell, J
    Gee, T
    Robinson, V
    Wells, G
    Bourne, RB
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S697 - S697
  • [34] Viscosupplementation with hylan G-F 20 in patients with osteoarthrosis of the knee
    Bert, Jack M.
    Waddell, David D.
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2010, 3 (03) : 127 - 132
  • [35] Prospective study of the safety and efficacy of hylan G-F 20 (Synvisc®) in patients with symptomatic ankle osteoarthritis.
    Witteveen, A. g. h.
    Giannini, S.
    Guido, G.
    Jerosch, J.
    Lohrer, H.
    van Dijk, C. N.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S676 - S676
  • [36] Efficacy of intra-articular Hylan G-F 20 on osteoarthritis of the knee
    Tetik, S
    Önes, K
    Tetik, C
    PAIN CLINIC, 2003, 15 (04): : 459 - 466
  • [37] THE EFFECTIVENESS AND COST-EFFECTIVENESS OF HYLAN G-F 20 IN OSTEOARTHRITIS OF THE KNEE
    Kostyuk, A.
    Almadiyeva, A.
    Akanov, A.
    VALUE IN HEALTH, 2015, 18 (07) : A647 - A647
  • [38] Sample sizes estimation in non-steroidal anti-inflammatory drugs (NSAIDs) trials by using either the OMERACT-OARSI set of sponder criteria or the single outcome 2 domain variables in knee osteoarthritis.
    Pham, T
    Baron, G
    Le Claire, P
    Ravaud, P
    Dougados, M
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S158 - S158
  • [39] Hylan G-F 20 reduces the probability of progression to total knee replacement in knee osteoarthritis
    Waddell, DD
    Bricker, DC
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 269 - 269
  • [40] HYLAN G-F 20 VERSUS TRIAMCINOLONE IN THE TREATMENT OF PRIMARY SHOULDER OSTEOARTHRITIS. RANDOMIZED TRIAL
    Tortato, Simone
    Pochini, Alberto De Castro
    Andreoli, Carlos Vicente
    Cohen, Carina
    Schmidt Lara, Paulo Henrique
    Belangero, Paulo Santoro
    Ejnisman, Benno
    ACTA ORTOPEDICA BRASILEIRA, 2022, 30 (01):
12345